Latest Pharma Insights
Senate Includes One-Month Delay On Lower THC Limits For Hemp In Continuing Resolution
Senate adds language to continuing resolution to delay imposing lower limit on all forms of THC allowed in lawful hemp rather than 0.3% concentration for delta-9 THC alone used to define de-scheduled hemp in 2018 farm bill.
HBW Insight - August 10, 2026
Senate adds language to continuing resolution to delay imposing lower limit on all forms of THC allowed in lawful hemp rather than 0.3% concentration for delta-9 THC alone used to define de-scheduled hemp in 2018 farm bill.
HBW Insight - August 10, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination in APAC.
Scrip - August 10, 2026
In this week's episode: Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination in APAC.
Scrip - August 10, 2026
Deals Shaping The Industry, July 2026
An interactive look at pharma, medtech and diagnostics deals made during July 2026. Data courtesy of Biomedtracker.
In Vivo - August 10, 2026
An interactive look at pharma, medtech and diagnostics deals made during July 2026. Data courtesy of Biomedtracker.
In Vivo - August 10, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination in APAC.
Scrip - August 10, 2026
In this week's episode: Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination in APAC.
Scrip - August 10, 2026
China’s New Five-Year Plan Signals Shift To Quality And Innovation
China’s 15th five-year plan elevates healthtech to a strategic national priority and increases the weighting on innovation and quality. This will have implications for volume-based procurement, the wording around which has altered. L.E.K. Consulting explained the rationale.
Medtech Insight - August 9, 2026
China’s 15th five-year plan elevates healthtech to a strategic national priority and increases the weighting on innovation and quality. This will have implications for volume-based procurement, the wording around which has altered. L.E.K. Consulting explained the rationale.
Medtech Insight - August 9, 2026
Senate Includes One-Month Delay On Lower THC Limits For Hemp In Continuing Resolution
Senate adds language to continuing resolution to delay imposing lower limit on all forms of THC allowed in lawful hemp rather than 0.3% concentration for delta-9 THC alone used to define de-scheduled hemp in 2018 farm bill.
HBW Insight - August 10, 2026
Senate adds language to continuing resolution to delay imposing lower limit on all forms of THC allowed in lawful hemp rather than 0.3% concentration for delta-9 THC alone used to define de-scheduled hemp in 2018 farm bill.
HBW Insight - August 10, 2026
Viatris Raises Outlook Despite $150m Manufacturing Hit
Viatris has raised its 2026 outlook despite a manufacturing disruption set to cost up to $150m in second-half sales, as stronger complex generics, transdermals and cost savings offset pressure from lower-margin products.
Generics Bulletin - August 7, 2026
Viatris has raised its 2026 outlook despite a manufacturing disruption set to cost up to $150m in second-half sales, as stronger complex generics, transdermals and cost savings offset pressure from lower-margin products.
Generics Bulletin - August 7, 2026
EU Urged To Reject ‘Industrially Unviable’ Export Restrictions
Medicines for Europe has urged the CJEU to reject limits on the SPC manufacturing waiver involving export storage, third-country marketing authorizations and foreign patent rights.
Generics Bulletin - August 7, 2026
Medicines for Europe has urged the CJEU to reject limits on the SPC manufacturing waiver involving export storage, third-country marketing authorizations and foreign patent rights.
Generics Bulletin - August 7, 2026
Diversification Gives Fresenius Kabi Room To Absorb Manufacturing Setbacks
Fresenius Kabi’s faster-growing businesses are overtaking its legacy pharma operations, helping offset fresh FDA scrutiny at Melrose Park as the firm’s Biopharma unit helps drive stronger financials.
Generics Bulletin - August 7, 2026
Fresenius Kabi’s faster-growing businesses are overtaking its legacy pharma operations, helping offset fresh FDA scrutiny at Melrose Park as the firm’s Biopharma unit helps drive stronger financials.
Generics Bulletin - August 7, 2026
Deals Shaping The Industry, July 2026
An interactive look at pharma, medtech and diagnostics deals made during July 2026. Data courtesy of Biomedtracker.
In Vivo - August 10, 2026
An interactive look at pharma, medtech and diagnostics deals made during July 2026. Data courtesy of Biomedtracker.
In Vivo - August 10, 2026